Literature DB >> 18587555

[Targeted therapy for metastatic bladder cancer].

F Vom Dorp1, C Börgermann, A Rose, M Becker, H Rübben.   

Abstract

The current therapy concept for metastatic bladder cancer is chemotherapy with gemcitabine and cisplatin as the first line protocol. Within the last 20 years no real progress could be achieved; the median survival is 14 months, though many different protocols have been tested. Expression analyses of growth factor receptors in human tumor tissue showed that expression of certain receptors is correlated with a severe clinical course.For many of these growth factor receptors pharmacological inhibitors are available in order to perform targeted therapy. The following review gives a survey of current studies on targeted therapy of metastatic bladder carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587555     DOI: 10.1007/s00120-008-1747-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

1.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; N Geller; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander
Journal:  Cancer       Date:  1989-12-15       Impact factor: 6.860

2.  Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder.

Authors:  P Lipponen; M Eskelinen; S Syrjänen; A Tervahauta; K Syrjänen
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

3.  HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.

Authors:  Stefan Krüger; Georg Weitsch; Hartwig Büttner; Arne Matthiensen; Torsten Böhmer; Tim Marquardt; Friedhelm Sayk; Alfred C Feller; Andreas Böhle
Journal:  Int J Cancer       Date:  2002-12-10       Impact factor: 7.396

4.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

5.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Authors:  P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

6.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Authors:  Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

7.  Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.

Authors:  Jose L Dominguez-Escrig; John D Kelly; David E Neal; Sonya M King; Barry R Davies
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

8.  Prognostic value of amplification of c-erb-B2 in bladder carcinoma.

Authors:  U Lönn; S Lönn; S Friberg; B Nilsson; C Silfverswärd; B Stenkvist
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

9.  HER-2--a possible target for therapy of metastatic urinary bladder carcinoma.

Authors:  Kenneth Wester; Anna Sjöström; Manuel de la Torre; Jörgen Carlsson; Per-Uno Malmström
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

  9 in total
  2 in total

1.  Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.

Authors:  A Rose; M Grandoch; F vom Dorp; H Rübben; A Rosenkranz; J W Fischer; A-A Weber
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Authors:  Karoly Szepeshazi; Andrew V Schally; Gunhild Keller; Norman L Block; Daniel Benten; Gabor Halmos; Luca Szalontay; Irving Vidaurre; Miklos Jaszberenyi; Ferenc G Rick
Journal:  Oncotarget       Date:  2012-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.